First-time AOM semaglutide prescribing increased by over 50%, marking the largest quarter-over-quarter increase in first-time AOM semaglutide prescribing since mid-2024, likely driven by the approval of the oral formulation of Wegovy in December 2025
The preparation is standardised prior to use, allowing researchers to work with a consistent peptide composition and eliminating variability associated with solution preparation
These pathways have main roles in immunomodulatory processes in asthma and are involved in the pathogenesis of all asthma clinical subtypes (i.e., intermittent, mild, moderate, and severe persistent)
Amelia-Yap ZH, Sofian-Azirun M, Chen CD, Lau KW, Suana IW, Syahputra E, et al
Some clinics have started using this as a core part of multi-modal hair protocols